PL378404A1 - Nowa odmiana krystaliczna 2-(3,5-bis-trifluorometylofenylo)-N-[6-(1,1-diokso-1<$Elambda>6 -tiomorfolin-4-ylo)-4-(4-fluoro-2-metylofenylo)pirydyn-3-ylo]-N-metyloizobutyroamidu - Google Patents

Nowa odmiana krystaliczna 2-(3,5-bis-trifluorometylofenylo)-N-[6-(1,1-diokso-1<$Elambda>6 -tiomorfolin-4-ylo)-4-(4-fluoro-2-metylofenylo)pirydyn-3-ylo]-N-metyloizobutyroamidu

Info

Publication number
PL378404A1
PL378404A1 PL378404A PL37840404A PL378404A1 PL 378404 A1 PL378404 A1 PL 378404A1 PL 378404 A PL378404 A PL 378404A PL 37840404 A PL37840404 A PL 37840404A PL 378404 A1 PL378404 A1 PL 378404A1
Authority
PL
Poland
Prior art keywords
phenyl
methyl
isobutyramide
thiomorpholin
dioxo
Prior art date
Application number
PL378404A
Other languages
English (en)
Inventor
Torsten Hoffmann
Fabienne Hoffmann-Emery
Sonia Nick
Urs Schwitter
Pius Waldmeier
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL378404A1 publication Critical patent/PL378404A1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL378404A 2003-01-31 2004-01-23 Nowa odmiana krystaliczna 2-(3,5-bis-trifluorometylofenylo)-N-[6-(1,1-diokso-1<$Elambda>6 -tiomorfolin-4-ylo)-4-(4-fluoro-2-metylofenylo)pirydyn-3-ylo]-N-metyloizobutyroamidu PL378404A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03002134 2003-01-31

Publications (1)

Publication Number Publication Date
PL378404A1 true PL378404A1 (pl) 2006-04-03

Family

ID=32798734

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378404A PL378404A1 (pl) 2003-01-31 2004-01-23 Nowa odmiana krystaliczna 2-(3,5-bis-trifluorometylofenylo)-N-[6-(1,1-diokso-1<$Elambda>6 -tiomorfolin-4-ylo)-4-(4-fluoro-2-metylofenylo)pirydyn-3-ylo]-N-metyloizobutyroamidu

Country Status (28)

Country Link
US (1) US7160881B2 (pl)
EP (1) EP1592428B1 (pl)
JP (1) JP5026702B2 (pl)
KR (1) KR100700421B1 (pl)
CN (1) CN100562320C (pl)
AR (1) AR042980A1 (pl)
AT (1) ATE366576T1 (pl)
AU (1) AU2004208483B8 (pl)
BR (1) BRPI0406702A (pl)
CA (1) CA2514037C (pl)
CL (1) CL2004000150A1 (pl)
CO (1) CO5580750A2 (pl)
DE (1) DE602004007486T2 (pl)
ES (1) ES2290666T3 (pl)
GT (1) GT200400009A (pl)
HR (1) HRP20050664A2 (pl)
IL (1) IL169600A (pl)
MX (1) MXPA05008171A (pl)
MY (1) MY135785A (pl)
NO (1) NO20053431L (pl)
NZ (1) NZ541243A (pl)
PA (1) PA8594601A1 (pl)
PE (1) PE20040944A1 (pl)
PL (1) PL378404A1 (pl)
RU (1) RU2330022C2 (pl)
TW (1) TWI293294B (pl)
WO (1) WO2004067007A1 (pl)
ZA (1) ZA200505567B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1776342B1 (en) 2004-07-06 2011-03-02 F. Hoffmann-La Roche AG Process for preparing carboxamide pyridine derivatives used as intermediates in the synthesis of nk-1 receptor antagonists
AU2006218193A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
SG178231A1 (en) * 2009-08-27 2012-03-29 Glaxosmithkline Llc Anhydrate forms of a pyridine derivative
CN103755592A (zh) * 2013-12-30 2014-04-30 镇江圣安医药有限公司 (2z)-氰基-3-羟基-n-[4-(三氟甲基)苯基]-2-丁烯酰胺的衍生物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2024507C1 (ru) * 1991-11-18 1994-12-15 Евгений Яковлевич Левитин 5-хлор-2-пиридиламид-4-нитро-n-(карбоксиметил)антраниловой кислоты, проявляющий противовоспалительную активность
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
CA2178219C (en) * 1993-12-29 2005-03-22 Raymond Baker Substituted morpholine derivatives and their use as therapeutic agents
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
DK1035115T3 (da) * 1999-02-24 2005-01-24 Hoffmann La Roche 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister
CN100398106C (zh) * 2001-04-23 2008-07-02 弗·哈夫曼-拉罗切有限公司 Nk-1受体拮抗剂对抗良性前列腺增生的用途
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides

Also Published As

Publication number Publication date
CL2004000150A1 (es) 2005-01-07
ZA200505567B (en) 2007-05-30
KR100700421B1 (ko) 2007-03-28
ATE366576T1 (de) 2007-08-15
JP2006514999A (ja) 2006-05-18
KR20050096964A (ko) 2005-10-06
PE20040944A1 (es) 2004-12-14
PA8594601A1 (es) 2004-09-16
AU2004208483A1 (en) 2004-08-12
IL169600A (en) 2010-11-30
ES2290666T3 (es) 2008-02-16
HRP20050664A2 (en) 2006-12-31
US7160881B2 (en) 2007-01-09
DE602004007486D1 (de) 2007-08-23
EP1592428A1 (en) 2005-11-09
AU2004208483B2 (en) 2008-03-06
NO20053431L (no) 2005-10-05
RU2330022C2 (ru) 2008-07-27
EP1592428B1 (en) 2007-07-11
DE602004007486T2 (de) 2008-04-30
MXPA05008171A (es) 2005-10-05
AU2004208483B8 (en) 2008-04-03
CA2514037C (en) 2012-03-13
CO5580750A2 (es) 2005-11-30
CN100562320C (zh) 2009-11-25
BRPI0406702A (pt) 2005-12-20
CN1744900A (zh) 2006-03-08
RU2005127216A (ru) 2006-04-10
WO2004067007A1 (en) 2004-08-12
CA2514037A1 (en) 2004-08-12
JP5026702B2 (ja) 2012-09-19
TW200510358A (en) 2005-03-16
GT200400009A (es) 2004-12-01
US20040186100A1 (en) 2004-09-23
AR042980A1 (es) 2005-07-13
MY135785A (en) 2008-06-30
NZ541243A (en) 2008-04-30
TWI293294B (en) 2008-02-11
NO20053431D0 (no) 2005-07-14

Similar Documents

Publication Publication Date Title
AU2003299474A8 (en) 2-4-(di-phenyl-amino)-pyrimidine derivatives useful for treating hyper-proliferative disorders
IL162721A0 (en) 2-(Pyridin-2-ylamino)-pyridoÄ2,3-dÜpyrimidin-7-ones
AU2003275716A1 (en) 3-benzoyl-2,4,5-substituted pyridine derivatives or salts thereof and bactericides containing the same
PL372944A1 (pl) 2,4-Dipodstawione pochodne pirymidyno-5-karboksyamidu jako modulatory kanału potasowego KCNQ
AU2003274025A1 (en) Pyridine derivatives useful as herbicides
SI1562902T1 (sl) 2-piridonski derivati kot inhibitorji nevtrofilneelastaze
IL176806A0 (en) Novel pyridine derivative and pyrimidine derivative (2)
PL377551A1 (pl) 5-Podstawione pirazynowe lub pirydynowe aktywatory glukokinazy
ATE472536T1 (de) Pyridin- und pyrimidin-derivate
IL160329A0 (en) 2-amino-4,5-trisubstituted thiazolyl derivatives
PL375990A1 (pl) Pochodne pirydyny jako modulatory receptora CB2
IL139868A (en) 2 - (3,5-bis - trifluoromethyl - phenyl) - n - methyl - n - (6-morpholin- 4 - yl - 4 - 0 - tolyl- pyridin - 3 - yl) - isobutyramide
HUP0401684A3 (en) Nicotinic acid-heterocyclyl-amides and analogous pyrimidine derivatives serving as pesticides
IL172230A0 (en) N-&#39;2-(2-pyridinyl) ethylbenzamide compounds and their use as fungicides
HUP0400398A3 (en) 2-(3,5-bis-trifluoromethyl-phenyl)-n-[6-(1,1-dioxo-1lambda6-thiomorpholin-4-yl)-4-(2-methyl or 4-fluoro-2-methyl substituted)phenyl-pyridin-3-yl]-n-methyl-isobutyramide
PL378404A1 (pl) Nowa odmiana krystaliczna 2-(3,5-bis-trifluorometylofenylo)-N-[6-(1,1-diokso-1&lt;$Elambda&gt;6 -tiomorfolin-4-ylo)-4-(4-fluoro-2-metylofenylo)pirydyn-3-ylo]-N-metyloizobutyroamidu
AU2003244181A1 (en) Phenoxypyridine derivative or salt thereof
IL159571A0 (en) 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[6-(1,1,-DIOXO-1lamda6-THIOMORPHOLIN-4-YL)-4-(2-METHYL OR 4-FLUORO-2-METHYL SUBSTITUTED) PHENYL-PYRIDIN-3-YL]-N-METHYL-ISOBUTYRAMIDE
PT1603910E (pt) Derivados de 2-(diaza-biciclo-alquil)-pirimidona substituídos
PL373280A1 (pl) Nowy sposób wytwarzania odmiany I N-(1-metyloetyloaminokarbonylo)-4-(3-metylofenyloamino)-3-pirydynosulfonamidu
PL353421A1 (pl) Nowe związki, pochodne symetrycznej 1,3,5-triazyny
AU2002337751A1 (en) Substituted 3-pyridyl pyrimidines as c17,20 lyase inhibitors
PL356412A1 (pl) Nowe związki, pochodne symetrycznej 1,3,5-triazyny
EP1829870A4 (en) 2- (PYRAZOL-1-YL) PYRIDINE DERIVATIVE
HK1057483A (en) 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)